Also categorized in Business of Medicine:
The first U.S. trials in people put CRISPR to the test in 2019
x hide permanently

FDA Approves Combination Treatment for Advanced Melanoma

Dermatology Times

Photo: Pixabay

dermatologytimes.com

The U.S. Food and Drug Administration has approved atezolizumab plus cobimetinib and vemurafenib for treatment of BRAF V600 mutation-positive advanced melanoma. Studies show the combination treatment prolonged patients’ lives by 15 months without disease worsening.

A new combination treatment from Genentech will be joining the skin cancer market with the recent approval by the U.S. Food and Drug Administration (FDA) for atezolizumab (Tecentriq) plus cobimetinib (Cotellic) and vemurafenib (Zelboraf) for treatment of BRAF V600 mutation-positive advanced melanoma. The FDA granted the supplemental Biologics License Application for atezolizumab under Priority Review.

The decision by the ...